Funded Projects › H2020
NECESSITY · NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease (AID) involving 0.5 to 3/1000 persons. The disease affects exocrine glands leading to dryness of the eyes and the mouth and is associated with fatigue and limb pain. In 30% to 50% of the patients, systemic and extra-glandular manifestations may develop. The spectrum of extra-glandular manifestations in pSS is broad and includes vasculitis, peripheral neuropathy, synovitis, kidney involvement and interstitial lung disease. Moreover, pSS patients have a 10 to 20-fold higher risk of developing B cell lymphomas, conferring shorter lifetime expectancy to these patients. Whereas 10 new targeted-immunomodulatory treatments have been marketed for rheumatoid arthritis in the past 20 years, only one drug has been licensed for other systemic AIDs, such as pSS and systemic erythematous lupus in the same period. There are several factors that may hamper the development of successful drugs for AID. Being multi-organ, these AIDs are considerably heterogeneous among individuals both in terms of clinical manifestations and biological disturbances, with, as a consequence, a great difficulty to set-up accurate composite clinical end-points sensitive to change and usable in clinical trials. In this project, our objectives are:• To develop and assess sensitive clinical endpoints, for use in future clinical trials, able to evaluate response to drug treatments in patients with pSS with high disease burden and/or systemic involvement,• To identify and evaluate discriminative biomarkers for stratification of pSS patients predictive of organ involvement and disease progression and thus available for inclusion in clinical trials,• To set-up and perform an original multi-arm multi-stage clinical trial to validate the newly defined pSS endpoints and the identified biomarkers, by maximizing the chance of finding a difference between the placebo arm and the treated arm.
Consortium · 29 organisations
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
FR · €932,235
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK
FR · €815,009
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
UK
ASSOCIATION FRANCAISE GOUGEROT-SJOGREN
FR · €50,000
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
EL · €130,319
UNIVERSITA DEGLI STUDI DI UDINE
IT · €100,000
NOVARTIS PHARMA AG
CH
UNIVERSITE DE BREST
FR · €427,719
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
FR · €2,729,817
ACADEMISCH ZIEKENHUIS GRONINGEN
NL · €137,661
THE UNIVERSITY OF BIRMINGHAM
UK · €327,402
UNIVERSITY OF NEWCASTLE UPON TYNE
UK · €380,573
HELSE STAVANGER HF
NO · €101,397
INNOVATION ACTA SRL
IT · €300,000
FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
ES · €226,675
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
NL · €196,493
INSTITUT PASTEUR
FR · €118,733
KAROLINSKA INSTITUTET
SE · €251,250
UNIVERSITE PARIS CITE
FR · €224,224
HOSPITAL CLINIC DE BARCELONA
ES
UNIVERSITE PARIS-SACLAY
FR
QUEEN MARY UNIVERSITY OF LONDON
UK · €342,941
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST
FR
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
FR
HOPITAUX UNIVERSITAIRES DE STRASBOURG
FR · €337,733
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.
ES · €50,000
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK
IE
UNIVERSITETET I BERGEN
NO · €19,819
BRISTOL-MYERS SQUIBB COMPANY CORP
US
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.